📣 VC round data is live. Check it out!

OrthoPediatrics Valuation Multiples

Discover OrthoPediatrics' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Imricor Medical Systems, Kamada, Medistim, Revenio Group and more.

OrthoPediatrics Overview

About OrthoPediatrics

OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.


Founded

2007

HQ

United States

Employees

562

Financials (LTM)

Revenue: $249M
EBITDA: $19M

EV

$484M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

OrthoPediatrics Financials

OrthoPediatrics reported last 12-month revenue of $249M and EBITDA of $19M.

In the same LTM period, OrthoPediatrics generated $182M in gross profit, $19M in EBITDA, and had net loss of ($34M).

Revenue (LTM)


OrthoPediatrics P&L

In the most recent fiscal year, OrthoPediatrics reported revenue of $236M and EBITDA of $15M.

OrthoPediatrics is unprofitable as of last fiscal year, with gross margin of 73%, EBITDA margin of 6%, and net margin of (17%).

See analyst estimates for OrthoPediatrics
LTMLast FY202320242025202620272028
Revenue$249M$236M$149M$205M$236M
Gross Profit$182M$173M$111M$149M$173M
Gross Margin73%73%75%73%73%
EBITDA$19M$15M($8M)($10M)($8M)
EBITDA Margin8%6%(6%)(5%)(3%)
EBIT Margin(13%)(12%)(17%)(14%)(12%)
Net Profit($34M)($40M)($21M)($38M)($40M)
Net Margin(14%)(17%)(14%)(18%)(17%)
Net Debt-$80M---

Financial data powered by Morningstar, Inc.

OrthoPediatrics Stock Performance

OrthoPediatrics has current market cap of $432M, and enterprise value of $484M.

Market Cap Evolution


OrthoPediatrics' stock price is $16.81.

OrthoPediatrics share price decreased by 2.1% in the last 30 days, and by 21.7% in the last year.

OrthoPediatrics has an EPS (earnings per share) of $-1.54.

See more trading valuation data for OrthoPediatrics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$484M$432M0.8%-2.1%5.9%-21.7%$-1.54

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

OrthoPediatrics Valuation Multiples

OrthoPediatrics trades at 1.9x EV/Revenue multiple, and 25.2x EV/EBITDA.

See NTM and 2027E valuation multiples for OrthoPediatrics

EV / Revenue (LTM)


OrthoPediatrics Financial Valuation Multiples

As of June 3, 2026, OrthoPediatrics has market cap of $432M and EV of $484M.

OrthoPediatrics has a P/E ratio of (12.6x).

LTMLast FY202320242025202620272028
EV/Revenue1.9x2.0x3.3x2.4x2.0x
EV/EBITDA25.2x32.8x(57.7x)(46.3x)(61.4x)
EV/EBIT(15.5x)(16.7x)(18.8x)(16.4x)(16.7x)
EV/Gross Profit2.7x2.8x4.3x3.3x2.8x
P/E(12.6x)(10.9x)(20.6x)(11.4x)(10.9x)
EV/FCF-(30.3x)(10.5x)(11.7x)(30.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified OrthoPediatrics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

OrthoPediatrics Margins & Growth Rates

OrthoPediatrics grew revenue by 12% and EBITDA by 71% in the last fiscal year.

In the most recent fiscal year, OrthoPediatrics reported gross margin of 73%, EBITDA margin of 6%, and net margin of (17%).

See estimated margins and future growth rates for OrthoPediatrics

OrthoPediatrics Margins

Last FY202420252026202720282029
Gross Margin73%73%73%73%
EBITDA Margin6%(5%)(3%)10%
EBIT Margin(12%)(14%)(12%)(8%)
Net Margin(17%)(18%)(17%)(10%)
FCF Margin(7%)(20%)(7%)0%

OrthoPediatrics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth12%38%15%12%
Gross Profit Growth12%34%16%12%
EBITDA Growth71%25%(25%)(421%)
EBIT Growth(31%)15%(2%)(31%)
Net Profit Growth(32%)80%5%(32%)
FCF Growth(100%)(10%)(61%)(100%)

Data powered by FactSet, Inc. and Morningstar, Inc.

OrthoPediatrics Operational KPIs

OrthoPediatrics' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.

OrthoPediatrics' Rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

OrthoPediatrics' Rule of X is 40% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for OrthoPediatrics
LTMLast FY202320242025202620272028
Rule of 4020%22%---
Bessemer Rule of X38%40%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.4M---
S&M Expenses to Revenue30%31%35%31%31%
G&A Expenses to Revenue49%51%51%50%51%
R&D Expenses to Revenue4%4%7%5%4%
Opex to Revenue-85%92%87%85%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

OrthoPediatrics Competitors

OrthoPediatrics competitors include Imricor Medical Systems, Kamada, Medistim, Revenio Group, Vicenne, Standard BioTools, Perspective Therapeutics, AngioDynamics, Tess Holdings Co and Medios.

Most OrthoPediatrics public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Imricor Medical Systems1456.5x264.3x(19.8x)(18.9x)
Kamada2.1x2.0x9.1x8.3x
Medistim5.6x5.5x16.6x18.2x
Revenio Group3.3x2.9x11.6x11.3x
Vicenne2.9x-12.6x-
Standard BioTools0.3x0.3x(0.4x)(0.6x)
Perspective Therapeutics162.7x213.0x(1.4x)(1.2x)
AngioDynamics1.4x1.3x54.4x33.3x

This data is available for Pro users. Sign up to see all OrthoPediatrics competitors and their valuation data.

Start Free Trial

OrthoPediatrics VC Funding History

Before going public, OrthoPediatrics raised $39M in total equity funding, across 1 round.


OrthoPediatrics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jun-14Undisclosed stage-$39M--

Acquisitions by OrthoPediatrics

OrthoPediatrics has acquired 4 companies to date.

Last acquisition by OrthoPediatrics was on January 8th 2024. OrthoPediatrics acquired Boston Orthotics & Prosthetics for $22M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by OrthoPediatrics

Boston Orthotics & Prosthetics
Pega Medical
MD Orthopaedics
ApiFix
Description
Boston Orthotics & Prosthetics is a Boston-based provider of pediatric orthotic and prosthetic devices affiliated with Children's Hospital. Established in 1902, it fabricates custom braces for scoliosis, clubfoot, and cerebral palsy using CAD-CAM design. The clinic treats 2,000 patients yearly with carbon fiber limbs and dynamic ankle-foot orthoses. Boston Orthotics & Prosthetics holds ABC certification and collaborates on prosthetics research at Harvard Medical School.
Pega Medical is a medical device company focused on trauma and deformity solutions for pediatric patients. It develops the Fassier-Duval Telescopic Intramedullary System, an implant that corrects bony deformities in children with osteogenesis imperfecta while allowing natural bone growth.
MD Orthopaedics is a North America-leading producer of nonsurgical clubfoot treatment devices and ankle-foot orthoses, distributing over 20 products including Ponseti-method boots, abduction bars, training kits, and accessories to 126 countries. The Iowa-based company employs 28 staff at its Cedar Falls facility, serving hundreds of thousands of patients through orthopedic clinics, hospitals, and Ponseti centers. As a member of the American Orthotic and Prosthetic Association, MD Orthopaedics maintains FDA clearance for its AFOs and provides clinician training materials endorsed by the International Federation of Ponseti Method.
ApiFix is a minimally invasive system for correcting adolescent idiopathic scoliosis in patients classified as Lenke Type 1 or Type 5 with Cobb angles between 35 and 55 degrees. The approach involves a single small incision followed by gradual correction over months through specialized physical therapy, avoiding the risks of extensive open surgery. Petah Tikva-based in Israel, ApiFix provides orthopedic surgeons with an outpatient alternative that preserves spinal growth potential while achieving deformity reduction.
HQ CountryUnited StatesCanadaUnited StatesIsrael
HQ City
Hartford, CT
Laval
Boston, MA
Misgav Dov
Deal Date8 Jan 202414 Jun 20224 Apr 20222 Apr 2020
Valuation$22M$33M$20M$67M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all OrthoPediatrics acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About OrthoPediatrics

When was OrthoPediatrics founded?OrthoPediatrics was founded in 2007.
Where is OrthoPediatrics headquartered?OrthoPediatrics is headquartered in United States.
How many employees does OrthoPediatrics have?As of today, OrthoPediatrics has over 562 employees.
Who is the CEO of OrthoPediatrics?OrthoPediatrics' CEO is David R. Bailey.
Is OrthoPediatrics publicly listed?Yes, OrthoPediatrics is a public company listed on Nasdaq.
What is the stock symbol of OrthoPediatrics?OrthoPediatrics trades under KIDS ticker.
When did OrthoPediatrics go public?OrthoPediatrics went public in 2017.
Who are competitors of OrthoPediatrics?OrthoPediatrics main competitors include Imricor Medical Systems, Kamada, Medistim, Revenio Group, Vicenne, Standard BioTools, Perspective Therapeutics, AngioDynamics, Tess Holdings Co, Medios.
What is the current market cap of OrthoPediatrics?OrthoPediatrics' current market cap is $432M.
What is the current revenue of OrthoPediatrics?OrthoPediatrics' last 12 months revenue is $249M.
What is the current revenue growth of OrthoPediatrics?OrthoPediatrics revenue growth (NTM/LTM) is 12%.
What is the current EV/Revenue multiple of OrthoPediatrics?Current revenue multiple of OrthoPediatrics is 1.9x.
What is the current EBITDA of OrthoPediatrics?OrthoPediatrics' last 12 months EBITDA is $19M.
What is OrthoPediatrics' EBITDA margin?OrthoPediatrics' last 12 months EBITDA margin is 8%.
What is the current EV/EBITDA multiple of OrthoPediatrics?Current EBITDA multiple of OrthoPediatrics is 25.2x.
How many companies OrthoPediatrics has acquired to date?As of June 2026, OrthoPediatrics has acquired 4 companies.
What was the largest acquisition by OrthoPediatrics?$67M acquisition of ApiFix on 2nd April 2020 was the largest M&A OrthoPediatrics has done to date.
What companies OrthoPediatrics acquired?OrthoPediatrics acquired ApiFix, Pega Medical, Boston Orthotics & Prosthetics, and MD Orthopaedics.
In how many companies OrthoPediatrics has invested to date?OrthoPediatrics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to OrthoPediatrics

Lists including OrthoPediatrics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial